268 related articles for article (PubMed ID: 1850462)
1. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
Paul D; Pick CG; Tive LA; Pasternak GW
J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
Gistrak MA; Paul D; Hahn EF; Pasternak GW
J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
[TBL] [Abstract][Full Text] [Related]
3. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
4. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
[TBL] [Abstract][Full Text] [Related]
5. Naloxone benzoylhydrazone (NalBzoH) analgesia.
Paul D; Levison JA; Howard DH; Pick CG; Hahn EF; Pasternak GW
J Pharmacol Exp Ther; 1990 Nov; 255(2):769-74. PubMed ID: 2173757
[TBL] [Abstract][Full Text] [Related]
6. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
[TBL] [Abstract][Full Text] [Related]
7. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids.
Kest B; McLemore G; Kao B; Inturrisi CE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1249-55. PubMed ID: 9400000
[TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
[TBL] [Abstract][Full Text] [Related]
9. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
Pick CG; Paul D; Pasternak GW
J Pharmacol Exp Ther; 1992 Sep; 262(3):1044-50. PubMed ID: 1326621
[TBL] [Abstract][Full Text] [Related]
10. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice.
Nakazawa T; Furuya Y; Kaneko T; Yamatsu K; Yoshino H; Tachibana S
J Pharmacol Exp Ther; 1990 Mar; 252(3):1247-54. PubMed ID: 1969472
[TBL] [Abstract][Full Text] [Related]
11. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
13. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice.
Hong EK; Takemori AE
J Pharmacol Exp Ther; 1989 Nov; 251(2):594-8. PubMed ID: 2553928
[TBL] [Abstract][Full Text] [Related]
14. Differential cross-tolerance between analgesia produced by alpha 2-adrenoceptor agonists and receptor subtype selective opioid treatments.
Paul D; Tran JG
Eur J Pharmacol; 1995 Jan; 272(1):111-4. PubMed ID: 7713142
[TBL] [Abstract][Full Text] [Related]
15. Selective antagonism of opioid analgesia by a sigma system.
Chien CC; Pasternak GW
J Pharmacol Exp Ther; 1994 Dec; 271(3):1583-90. PubMed ID: 7996472
[TBL] [Abstract][Full Text] [Related]
16. Kappa opioid analgesia is dependent on serotonergic mechanisms.
Vonvoigtlander PF; Lewis RA; Neff GL
J Pharmacol Exp Ther; 1984 Nov; 231(2):270-4. PubMed ID: 6092612
[TBL] [Abstract][Full Text] [Related]
17. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
18. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
19. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
20. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
